Swedbank AB Purchases 786 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Swedbank AB raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,489 shares of the medical research company’s stock after purchasing an additional 786 shares during the quarter. Swedbank AB owned 0.05% of IQVIA worth $21,680,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of IQV. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the second quarter valued at $27,000. Capital Performance Advisors LLP purchased a new position in IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp bought a new stake in IQVIA during the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of IQV stock opened at $204.02 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The business’s fifty day simple moving average is $221.96 and its 200-day simple moving average is $226.98. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $37.03 billion, a PE ratio of 26.77, a PEG ratio of 2.08 and a beta of 1.51.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.